^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Regimen: | (cisplatin + docetaxel + Erbitux (cetuximab)) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
A summary of management strategies for recurrent and/or metastatic SCCHN...No platinum-based ChT during the last 6 months and PD-L1-negative tumour...Options...TPeX...
